NOVARTIS AG
NOVN
 Delayed - 04/15 11:31:49 am |
|
| 80.53CHF | +0.81% |
Business Summary
| Healthcare | ||||
 | Pharmaceuticals & Medical Research | |||
| Pharmaceuticals | |||
| Pharmaceuticals | |||
| Other Pharmaceuticals | |||
Novartis is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- pharmaceutical products (79.5%): used to treat cardiovascular, respiratory, and dermatological diseases, gastrointestinal disorders, cancers, central nervous system disorders, hormone imbalances, etc.;
- generic drugs (20.5%; Sandoz).
Net sales break down geographically as follows: Switzerland (1.7%), Germany (8.7%), France (5.1%), Europe (22.3%), the United States (34.3%), Americas (7.2%) and Asia/Africa/Australasia (20.7%).
On 9 April 2019, the group finalised the spin-off of Alcon.
Number of employees : 105 794 people.
- pharmaceutical products (79.5%): used to treat cardiovascular, respiratory, and dermatological diseases, gastrointestinal disorders, cancers, central nervous system disorders, hormone imbalances, etc.;
- generic drugs (20.5%; Sandoz).
Net sales break down geographically as follows: Switzerland (1.7%), Germany (8.7%), France (5.1%), Europe (22.3%), the United States (34.3%), Americas (7.2%) and Asia/Africa/Australasia (20.7%).
On 9 April 2019, the group finalised the spin-off of Alcon.
Number of employees : 105 794 people.
Sales per Business
| 2019 | 2020 | |||
| CHF (in Million) | % | CHF (in Million) | % | |
| Innovative Medicines | 37,480 | 79.4% | 36,618 | 80.2% |
| Sandoz | 9,671 | 20.5% | 9,054 | 19.8% |
Sales per region
| 2020 | ||
| CHF (in Million) | % | |
| United States | 15,472 | 33.9% |
| Europe | 10,283 | 22.5% |
| Asia/Africa/Australasia | 4,545 | 10% |
| Germany | 4,241 | 9.3% |
| Canada and Latin America | 3,042 | 6.7% |
| Japan | 2,632 | 5.8% |
| China | 2,415 | 5.3% |
| France | 2,292 | 5% |
| Switzerland | 750.89 | 1.6% |
Managers
| Name | Title |
| Vasant Narasimhan | Chief Executive Officer |
| Harry Werner Kirsch | Chief Financial Officer |
| Hans Jörg Reinhardt | Independent Non-Executive Chairman |
| John Tsai | Chief Medical Officer |
| Klaus Moosmayer | Chief Ethics Risk & Compliance Officer |
| Andreas von Planta | Independent Non-Executive Director |
| Ann Marie Fudge | Independent Non-Executive Director |
| Enrico Cipro Vanni | Vice Chairman |
| Charles L. Sawyers | Independent Non-Executive Director |
| William Thomas Winters | Independent Non-Executive Director |
| Shareholders |
| Name | Equities | % |
| Novartis AG | 210,238,872 | 8.52% |
| Sandoz Family Foundation | 89,135,960 | 3.61% |
| The Vanguard Group, Inc. | 57,327,726 | 2.32% |
| UBS Asset Management Switzerland AG | 56,764,402 | 2.30% |
| Norges Bank Investment Management | 56,446,398 | 2.29% |
| Novartis Foundation For Employee Participation | 49,094,512 | 1.99% |
| Wellington Management Co. LLP | 44,527,903 | 1.80% |
| Capital Research & Management Co. (Global Investors) | 32,337,163 | 1.31% |
| Credit Suisse Asset Management (Schweiz) AG | 31,469,445 | 1.28% |
| Zürcher Kantonalbank (Investment Management) | 24,245,426 | 0.98% |
Company contact information
Lichtstrasse 35
CH-4056 Basel, Basel-Stadt
Phone : +41 61 324 11 11
Fax : +41 61 324 80 01
web site : http://www.novartis.com
CH-4056 Basel, Basel-Stadt
Phone : +41 61 324 11 11
Fax : +41 61 324 80 01
web site : http://www.novartis.com
Markets and indexes
| - |
| - Domestic Standard |
| - SMI / FTSE Eurotop 100, Low Carbon 100 Europe, Stoxx Europe 50, STOXX Europe 600, Stoxx Global 200 |
Stock Exchange Codes
| - Reuters Code : | NOVN.S |
| - Datastream Code : | S:NOVS |
Sector Other Pharmaceuticals
| 1st jan. | Capi. (M$) | ||
 | |||
| NOVARTIS AG | -1.90% | 195 369 | |
| |||
| JOHNSON & JOHNSON | 1.61% | 421 022 | |
| ROCHE HOLDING AG | -0.02% | 288 425 | |
| PFIZER INC. | 0.95% | 207 340 | |
| NOVARTIS AG | -4.51% | 195 369 | |
| MERCK & CO., INC. | -6.60% | 193 391 | |
| ABBVIE INC. | -1.17% | 186 895 | |
| ELI LILLY AND COMPANY | 8.39% | 166 346 | |
| NOVO NORDISK A/S | 2.82% | 162 882 | |
| AMGEN INC. | 8.71% | 143 732 | |
| BRISTOL-MYERS SQUIBB COMPANY | 2.50% | 142 547 | |
| ASTRAZENECA PLC | -0.72% | 131 672 | |
| SANOFI | 6.73% | 125 614 | |
| GLAXOSMITHKLINE PLC | -3.90% | 88 637 | |
| JIANGSU HENGRUI MEDICINE CO., LTD. | -26.27% | 69 532 | |
| CHUGAI PHARMACEUTICAL CO., LTD. | -22.28% | 64 689 | |
| ALLERGAN PLC | 0.97% | 63 659 | |
| BAYER AG | 9.85% | 62 225 | |
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | -1.07% | 53 139 | |
| DAIICHI SANKYO COMPANY, LIMITED | -14.71% | 52 365 | |
| ASTELLAS PHARMA INC. | 3.73% | 28 058 | |
Brand Portfolio
